

Provided by:



Allogeneic Stem Cell Transplantation Rounds 2021-2022

Allogeneic Stem Cell Transplantation Rounds 2021-2022 - 8/5/2021

August 5, 2021

1:00 PM - 2:00 PM

Perelman Center for Advanced Medicine

Target Audience

This program has been designed for Internal Medicine - Hematology, Internal Medicine - Medical Oncology

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Identify and discuss from an interprofessional perspective appropriate candidates for transplant based on many factors including infectious disease risks, comorbidity risks, disease specific risk factors. Patient selection will require consideration of many of these disease factors.
- 2 Assess the likelihood of developing C. difficile as well as methods to prevent transmission, the unique risks associated with this infection in transplant patients, and list methods that prevent infection including how practice changes effect outcomes.
- 3 Describe outcomes after allogeneic stem cell transplantation for patients with refractory AML or advanced MDS, including an outline of new treatment practices that may impact outcomes, and from an interprofessional perspective discuss availabilities of novel clinical trials and outcomes associated with new approaches
- 4 Describe differences and potential risks and benefits associated with different donor choices from an interprofessional perspective with an emphasis on developing a consistent approach to donor selection through systematic evaluation of various options.

Session Educational Objectives

After completing this educational activity, participants should be able to:

- 1 Identify and discuss from an interprofessional perspective appropriate candidates for transplant based on many factors including infectious disease risks, comorbidity risks, disease specific risk factors. Patient selection will require consideration of many of these disease factors.
- 2 Assess the likelihood of developing C. difficile as well as methods to prevent transmission, the unique risks associated with this infection in transplant patients, and list methods that prevent infection including how practice changes effect outcomes.
- 3 Describe outcomes after allogeneic stem cell transplantation for patients with refractory AML or advanced MDS, including an outline of new treatment practices that may impact outcomes, and from an interprofessional perspective discuss availabilities of novel clinical trials and outcomes associated with new approaches
- 4 Describe differences and potential risks and benefits associated with different donor choices from an interprofessional perspective with an emphasis on developing a consistent approach to donor selection through systematic evaluation of various options.

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For more information, please contact
Jazmin Tunstall
(215) 662-2862
Jazmin.Tunstall@uphs.upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is approved for **1.00** contact hours
UAN Number: JA0000324-0000-21-007-L04-P

PAs: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*

None

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provide products or services that may be relevant to the content of this continuing education activity. For this purpose, we consider relationships of the person involved to include financial relationships of a spouse or partner.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain relationships that created a conflict of interest relevant to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity. Any peer reviewer with a potential conflict of interest will recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of commercial interest/Nature of relationship
Noelle V. Frey	Co-Director	Husband Employer-Merck and Company, Inc.- Infectious Disease Consultant-Kite-Oncology - 02/09/2021
David L Porter, MD	Co-Director	Holder of Intellectual Property Rights-Novartis AG-CAR T cells Grants/Research Support Recipient-Novartis AG-CAR T cells Spouse, former employment- Genentech, Inc.-N/A Advisor or Review Panel Member-Kite Pharm-CAR T cells Advisor or Review Panel Member-Incyte-GVHD Advisor or Review Panel Member-Novartis AG-CAR T cells Advisor or Review Panel Member-Jazz-VOD Board Member-National Marrow Donor Program-Bone marrow transplant and cell therapy Advisor or Review Panel Member-Janssen-Hematology Advisor or Review Panel Member-DeCART-CAR T cells Holder of Intellectual Property Rights-Tmunity-CAR T cells Stock Shareholder (excluding mutual funds)-Genentech, Inc.-NA - 07/12/2021
Alison W Loren, MD, MSCE	Course Director, Faculty	Nothing to disclose - 08/22/2019
Jacqueline Smith, CRNP	Nurse Planner	Nothing to disclose - 11/19/2020
Elizabeth Hexner, MD	Other Planning Committee Member	Grants/Research Support Recipient-Blueprint Medicines Grants/Research Support Recipient-Tmunity Therapeutics Advisor or Review Panel Member-Blueprint Medicines Exam committee member-American Board of Internal Medicine -

		06/21/2021
Alison Carulli, PharmD	Pharmacy Planner	Nothing to disclose - 11/16/2020

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected